PAVmed Projects Q3 Non-GAAP Adjusted Net Loss of $1.2 Million
Medical technology company PAVmed (PAVM) has issued a preliminary financial outlook for the third quarter, projecting a non-GAAP adjusted net loss of approximately $1.2 million. This equates to an estimated loss of $0.19 per common share. The company reported that operating expenses for the period are expected to be roughly $6.8 million. Notably, this expenditure includes $1.0 million in stock-based compensation expenses.
Tickers: $PAVM